IMVEXXY (estradiol) by Pfizer is estrogen receptor agonists [moa]. First approved in 2018.
Drug data last refreshed 28m ago · AI intelligence enriched 3h ago
IMVEXXY is a vaginal estradiol insert approved by the FDA in 2018 for the treatment of moderate-to-severe dyspareunia associated with menopausal atrophy. It works as an estrogen receptor agonist to restore vaginal tissue health and function. The product represents a localized hormone therapy approach with minimal systemic absorption.
Product is at peak commercial maturity with $13M in Medicare Part D spending; the small patient base and stable trend suggest a focused, specialized commercial team rather than broad-based field expansion.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on IMVEXXY at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moIMVEXXY roles are concentrated in commercial, medical affairs, and market access functions serving a specialized, niche patient population with limited but stable revenue. Career growth on this team emphasizes payer management, specialist engagement, and defensive franchise strategies rather than launch excitement or rapid scaling.